AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16834836 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg/day or olmesartan 20 mg/day plus 12.5 mg hydrochlorothiazide for 4 weeks (non-controlled patients)
Number of subjects: 823
Study 14971627 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for GPs in assessment and management of depression
Number of subjects: 189
Study 10656838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity language messages
Number of subjects: 841
Study 10656838 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity language messages
Number of subjects: 841
Study 10656838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity language with deductive argument style
Number of subjects: 841
Study 10656838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity language with inductive argument style
Number of subjects: 841
Study 9088813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 5 mg
Number of subjects: 0
Study 9088813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 1 mg
Number of subjects: 0
Study 9088813 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20 mL (Control)
Number of subjects: 0
Study 8258574 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect photographic method
Number of subjects: 0
Study 8258574 — intervention group
Group type: COMPARATOR
Intervention: Direct method
Number of subjects: 0
Study 3512926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received all interventions including mailed packets, appointment reminders, and follow-up)
Number of subjects: 859
Study 3512926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 859
Study 30790098 — intervention group
Group type: EXPERIMENTAL
Intervention: Family accommodation (FA)
Number of subjects: 150
Study 30790098 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 150
Study 30790098 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing and externalizing problems
Number of subjects: 150
Study 28389421 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based e-screening
Number of subjects: 636
Study 28389421 — intervention group
Group type: COMPARATOR
Intervention: Paper-based screening
Number of subjects: 636
Study 25170994 — intervention group
Group type: EXPERIMENTAL
Intervention: HERMITAGE intervention (n=350)
Number of subjects: 700
Study 25170994 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (n=350)
Number of subjects: 700
Study 25170994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 700
Study 22648289 — intervention group
Group type: EXPERIMENTAL
Intervention: rasburicase
Number of subjects: 26
Study 22648289 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 21753777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (twice a week for 6 months, emphasizing swimming)
Number of subjects: 35
Study 21753777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 35
Study 20110025 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 1200 mg/d (400 mg TID)
Number of subjects: 134
Study 20110025 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone 1000 mg/d (once daily in the evening)
Number of subjects: 134
Study 17126782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg
Number of subjects: 160
Study 17126782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 160
Study 17126782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 160
Study 17126782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 160
Study 15067407 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodwin‐Hohenfellner technique
Number of subjects: 83
Study 15067407 — intervention group
Group type: EXPERIMENTAL
Intervention: Abol‐Enein modification
Number of subjects: 83
Study 15067407 — intervention group
Group type: EXPERIMENTAL
Intervention: Le‐Duc procedure
Number of subjects: 83
Study 15067407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainz pouch II
Number of subjects: 83
Study 11902591 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ‐1a)
Number of subjects: 0
Study 11902591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9277010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 939
Study 9277010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study 8339409 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin prophylaxis (adjusted to prolong INR to 1.5 on the day of surgery and 2.5 after surgery)
Number of subjects: 97
Study 8339409 — intervention group
Group type: EXPERIMENTAL
Intervention: NPA measurement
Number of subjects: 97
Study 8339409 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin time index and INR
Number of subjects: 97
Study 8339409 — intervention group
Group type: COMPARATOR
Intervention: Transfusion on the day of surgery
Number of subjects: 97
Study 8339409 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin time index, INR, and NPA concentration
Number of subjects: 97
Study 3711364 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 3711364 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 3711364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 30734696 — intervention group
Group type: COMPARATOR
Intervention: Baseline mortality risk
Number of subjects: 0
Study 30334917 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader graft technique
Number of subjects: 210
Study 30334917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress suture technique
Number of subjects: 210
Study 30334917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no graft and suture)
Number of subjects: 210
Study 26679955 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression regulation intervention plus supportive contact
Number of subjects: 40
Study 26679955 — intervention group
Group type: COMPARATOR
Intervention: Supportive contact only
Number of subjects: 40
Study 24996842 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy for 6 weeks
Number of subjects: 37
Study 24996842 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 37
Study 24996842 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 37
Study 24996842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22341825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer programme (conditional and unconditional)
Number of subjects: 1289
Study 20038863 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 86
Study 20038863 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode grid laser
Number of subjects: 86
Study 20038863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 20038863 — intervention group
Group type: COMPARATOR
Intervention: Standard Early Treatment Diabetic Retinopathy Study focal laser treatment
Number of subjects: 86
Study 18268090 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 80
Study 16580904 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice daily on the first day and 200 mg twice daily on the second day)
Number of subjects: 10
Study 16580904 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 10
Study 16580904 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 10
Study 12757533 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cell processor
Number of subjects: 40
Study 12757533 — intervention group
Group type: COMPARATOR
Intervention: Standard centrifugation technique
Number of subjects: 40
Study 10991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine
Number of subjects: 2532
Study 9296215 — intervention group
Group type: EXPERIMENTAL
Intervention: Molgramostim 5 micrograms/kg every 12 hours for 14 days, given alongside chemotherapy regimens.
Number of subjects: 21
Study 8466730 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine
Number of subjects: 268
Study 8466730 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 268
Study 8466730 — intervention group
Group type: COMPARATOR
Intervention: methyldopa
Number of subjects: 268
Study 8466730 — intervention group
Group type: COMPARATOR
Intervention: normotensive subjects
Number of subjects: 268
Study 3892383 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 20
Study 3892383 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 20
Study 30606383 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography using low-voltage (80 kVp) and low-concentration contrast media (300 mgI/ml) with IMR algorithm
Number of subjects: 71
Study 30606383 — intervention group
Group type: COMPARATOR
Intervention: CT angiography using regular voltage (100 kVp) and higher concentration contrast media (370 mgI/ml) with hybrid iterative reconstruction technique
Number of subjects: 71
Study 26907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 12 weeks
Number of subjects: 333
Study 26907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 24 weeks
Number of subjects: 333
Study 24310443 — intervention group
Group type: EXPERIMENTAL
Intervention: Orocutaneous stimulation during gavage feedings
Number of subjects: 22
Study 24310443 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (control)
Number of subjects: 22
Study 22269678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh corneal graft
Number of subjects: 37
Study 22269678 — intervention group
Group type: COMPARATOR
Intervention: Frozen corneal graft
Number of subjects: 37
Study 22269678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 19787345 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic guidance
Number of subjects: 0
Study 19787345 — intervention group
Group type: EXPERIMENTAL
Intervention: Error amplification
Number of subjects: 0
Study 18366766 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label continuous combined hormone therapy
Number of subjects: 1823
Study 18366766 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1823
Study 18366766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 1823
Study 18366766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1823
Study 15604942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring using (99m)Tc-Sestamibi scintimammography
Number of subjects: 26
Study 15552853 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth in malocclusion
Number of subjects: 83
Study 15552853 — intervention group
Group type: COMPARATOR
Intervention: Teeth in normal occlusion
Number of subjects: 83
Study 15552853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp vitality threshold
Number of subjects: 83
Study 10482155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Ejection Fraction (<55%)
Number of subjects: 212
Study 10482155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Stress-Corrected MWS (<89.2%)
Number of subjects: 212
Study 10482155 — intervention group
Group type: COMPARATOR
Intervention: Normal Ejection Fraction (>55%)
Number of subjects: 212
Study 10482155 — intervention group
Group type: COMPARATOR
Intervention: Normal Stress-Corrected MWS (>89.2%)
Number of subjects: 212
Study 8618181 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 29
Study 8618181 — intervention group
Group type: COMPARATOR
Intervention: cisapride
Number of subjects: 29
Study 1656149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 1656149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6633596 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of progesterone receptors
Number of subjects: 189
Study 6633596 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of estrogen receptors
Number of subjects: 189
Study 6633596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estrogen and progesterone receptors
Number of subjects: 189
Study 31827353 — intervention group
Group type: EXPERIMENTAL
Intervention: On-ice agility training
Number of subjects: 14
Study 31827353 — intervention group
Group type: COMPARATOR
Intervention: Off-ice agility training
Number of subjects: 14
Study 31827353 — intervention group
Group type: COMPARATOR
Intervention: Comparison of training effects
Number of subjects: 14
Study 29126981 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1200 mg
Number of subjects: 84
Study 29126981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26857782 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg ropivacaine plus 5 μg dexmedetomidine (RD)
Number of subjects: 108
Study 26857782 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg ropivacaine plus 15 μg fentanyl (RF)
Number of subjects: 108
Study 26857782 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg ropivacaine (R)
Number of subjects: 108
Study 25164793 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran extract (WBE)
Number of subjects: 19
Study 25164793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 19
Study 25164793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22222291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) in alcohol (more than 0.5%)
Number of subjects: 0
Study 19153116 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-3 (irinotecan 100 mg/m(2) days 1 and 3 combined with LV 400 mg/m(2) day 1 and 46-h continuous 5-FU 2000 mg/m(2))
Number of subjects: 342
Study 19153116 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-1 (irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2))
Number of subjects: 342
Study 19153116 — intervention group
Group type: EXPERIMENTAL
Intervention: Other irinotecan-based regimens
Number of subjects: 342
Study 17472599 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 478
Study 17472599 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 478
Study 15182413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Number of subjects: 363
Study 15182413 — intervention group
Group type: COMPARATOR
Intervention: 3 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Number of subjects: 363
Study 15182413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis
Number of subjects: 363
Study 15182413 — intervention group
Group type: COMPARATOR
Intervention: 3 day antibiotic prophylaxis
Number of subjects: 363
Study 12201823 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.5 IU/m2
Number of subjects: 17
Study 12201823 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 3.0 IU/m2
Number of subjects: 17
Study 12201823 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 6.0 IU/m2
Number of subjects: 17
Study 12201823 — intervention group
Group type: COMPARATOR
Intervention: Non-GH treatment
Number of subjects: 17
Study 9812183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose standard heparin 300 U/kg as an intravenous bolus
Number of subjects: 48
Study 9812183 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus
Number of subjects: 48
Study 8588268 — intervention group
Group type: EXPERIMENTAL
Intervention: Right adrenalectomy with liver mobilization
Number of subjects: 21
Study 8588268 — intervention group
Group type: COMPARATOR
Intervention: Right adrenalectomy without mobilizing the liver
Number of subjects: 21
Study 2693117 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 10 mg.kg‐1
Number of subjects: 15
Study 2693117 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 20 mg.kg‐1
Number of subjects: 15
Study 2693117 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) at 100 mg.kg‐1
Number of subjects: 15
Study 2693117 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4‐MP) overall
Number of subjects: 15
Study 2693117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide
Number of subjects: 287
Study 648211 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 287
Study 648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus CCNU
Number of subjects: 287
Study 648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus CCNU
Number of subjects: 287
Study 31541626 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted sedated C-EGD
Number of subjects: 437
Study 31541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsated U-TOE
Number of subjects: 437
Study 31541626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsated C-EGD
Number of subjects: 437
Study 31541626 — intervention group
Group type: COMPARATOR
Intervention: AI subgroup (sedated C-EGD)
Number of subjects: 437
Study 31541626 — intervention group
Group type: COMPARATOR
Intervention: AI subgroup (unsedated U-TOE)
Number of subjects: 437
Study 31541626 — intervention group
Group type: COMPARATOR
Intervention: AI subgroup (unsedated C-EGD)
Number of subjects: 437
Study 30632155 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 CDC-based PA strategies
Number of subjects: 4894
Study 30632155 — intervention group
Group type: COMPARATOR
Intervention: Routine PA programs
Number of subjects: 4894
Study 28651249 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO40303 (intravenous bolus)
Number of subjects: 163
Study 28651249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 25604090 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention for low-income adolescent mothers; delivered via a web-based application over 6 weeks, includes daily behavioral challenges, text message reminders, discussion forums, and website information.
Number of subjects: 100
Study 25604090 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group); participants continue to receive usual care during the intervention.
Number of subjects: 100
Study 23882457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 16
Study 23882457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21478219 — intervention group
Group type: EXPERIMENTAL
Intervention: CT score
Number of subjects: 39
Study 21478219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function (expressed as Z-scores)
Number of subjects: 39
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Switching to another SSRI
Number of subjects: 0
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Switching to a dual reuptake inhibitor
Number of subjects: 0
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Switching to another mechanism of action
Number of subjects: 0
Study 19543563 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation strategies
Number of subjects: 0
Study 19543563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 19543563 — intervention group
Group type: EXPERIMENTAL
Intervention: T3
Number of subjects: 0
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy as a switch or augmentation strategy
Number of subjects: 0
Study 19543563 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants in augmentation
Number of subjects: 0
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Remission rates
Number of subjects: 0
Study 19543563 — intervention group
Group type: COMPARATOR
Intervention: Recurrence rates
Number of subjects: 0
Study 19543563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients achieving remission
Number of subjects: 0
Study 17465354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulna implants with surrounding bone blocks
Number of subjects: 20
Study 17465354 — intervention group
Group type: COMPARATOR
Intervention: Conventional sinus augmentation with particulated autogenous bone grafts
Number of subjects: 20
Study 15649285 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO (100 mg) tablets
Number of subjects: 81
Study 15649285 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (P group) containing vitamins C (25 mg) and E (5 mg)
Number of subjects: 81
Study 11257292 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtensile test method
Number of subjects: 40
Study 11257292 — intervention group
Group type: COMPARATOR
Intervention: Chevron-notched short-bar (CNSB) test method
Number of subjects: 40
Study 9533351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical treatment with oral agents and exogenous insulin injection
Number of subjects: 0
Study 7546098 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Group underpad
Number of subjects: 107
Study 7546098 — intervention group
Group type: COMPARATOR
Intervention: Reference Group underpad
Number of subjects: 107
Study 3391875 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg
Number of subjects: 29
Study 3391875 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (EB) enterotablet A 500 mg
Number of subjects: 29
Study 3391875 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterotablet B 500 mg
Number of subjects: 29
Study 3391875 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (EB) enterotablet A 500 mg (multiple dosing)
Number of subjects: 29